Endothelin-1-induced pain and hyperalgesia: a review of pathophysiology, clinical manifestations and future therapeutic options
G Hans, K Deseure, H Adriaensen - Neuropeptides, 2008 - Elsevier
Pain in patients with metastatic cancer contributes to increased suffering in those already
burdened by their advancing illness. The causes of this pain are unknown, but are likely to
involve the action of tumour-associated mediators and their receptors. In recent years,
several chemical mediators have increasingly come to the forefront in the pathophysiology
of cancer pain. One such mediator, endothelin-1 (ET-1), is a peptide of 21 amino acids that
was initially shown to be a potent vasoconstrictor. Extensive research has revealed that …
burdened by their advancing illness. The causes of this pain are unknown, but are likely to
involve the action of tumour-associated mediators and their receptors. In recent years,
several chemical mediators have increasingly come to the forefront in the pathophysiology
of cancer pain. One such mediator, endothelin-1 (ET-1), is a peptide of 21 amino acids that
was initially shown to be a potent vasoconstrictor. Extensive research has revealed that …